Snapshot from Aug 20, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Plus Therapeutics rebrands to Cerenome
Business corporate rebranding

Plus Therapeutics rebrands to Cerenome

Analysis based on 6 articles · First reported Jul 31, 2026 · Last updated Aug 03, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The rebranding and ticker change to CNSY may attract new investors and increase visibility, potentially supporting the stock price. The integration of diagnostics, therapeutics, and AI could enhance the company's long-term growth prospects, though clinical and regulatory risks remain.

Biotechnology Healthcare Artificial Intelligence
Event Summary

MiNK Therapeutics, Inc., a CNS oncology company, announced on July 31, 2026, that its corporate rebrand to Cerenome, Inc. will be completed as scheduled. Effective August 3, 2026, the company will trade on the Nasdaq Capital Market Capital Market under the new ticker symbol 'CNSY'. The rebrand reflects the company's evolution from a therapeutics-focused organization into an integrated CNS oncology company that combines precision diagnostics, targeted therapeutics, and artificial intelligence. The company's strategy is built on three platforms: the CNSide Diagnostic, a commercially available cerebrospinal fluid-based testing platform; REYOBIQ, an investigational targeted radiotherapeutic in clinical trials; and a proprietary data analytics and AI platform. The company also highlighted its recent artificial intelligence partnership with Ephemeral Technologies. The name change does not affect shareholders' ownership interests, and existing shares will automatically reflect the new name and ticker. The company's stock closed at $3.87, up 6.03% on the announcement day.

Key Actions
100 MiNK Therapeutics rebranded to Cerenome
80 MiNK Therapeutics changed ticker Nasdaq Capital Market
70 Cerenome partnered with Ephemeral Technologies
Entities Involved
stock
MiNK Therapeutics
MiNK Therapeutics is the entity undergoing the rebrand to Cerenome, Inc. The change to a new name and ticker symbol reflects its strategic shift toward an integrated CNS oncology platform, which may positively influence investor perception.
Importance 100.0 Sentiment 10.0
stock
Cerenome
Cerenome is the new corporate identity of MiNK Therapeutics, effective August 3, 2026. It will trade under the ticker CNSY and aims to integrate diagnostics, therapeutics, and AI to improve CNS cancer care, potentially enhancing its market position.
Importance 100.0 Sentiment 10.0
per
Marc H. Hedrick
Marc H. Hedrick is the President and CEO of Cerenome. He is leading the company's strategic transformation and communicated the rebranding, which is central to the event.
Importance 60.0 Sentiment 10.0
priv
Ephemeral Technologies
Ephemeral Technologies is the AI partner of Cerenome. The partnership is part of Cerenome's integrated platform strategy, potentially enhancing its data analytics and AI capabilities.
Importance 40.0 Sentiment 10.0
exch
Nasdaq Capital Market
Nasdaq Capital Market is the exchange where Cerenome's stock will continue to trade under the new ticker CNSY. The listing change is a procedural aspect of the rebranding.
Importance 30.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.